Anteris secures CMS Medicare reimbursement eligibility for PARADIGM trial under TAVR policy
PUBT · 04/28 10:24
Share
Listen to the news
- Anteris Technologies secured U.S. Medicare reimbursement eligibility for its global pivotal PARADIGM Trial under a CMS national coverage policy.
- Eligible procedures at participating U.S. study sites will be covered under the TAVR National Coverage Determination 20.32.
- The Coverage with Evidence Development framework is expected to support U.S. site activation for the PARADIGM Trial.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Anteris Technologies Global Corp. published the original content used to generate this news brief on April 28, 2026, and is solely responsible for the information contained therein.
Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending
No content on the Webull website shall be considered a recommendation or solicitation for the purchase or sale of securities, options or other investment products. All information and data on the website is for reference only and no historical data shall be considered as the basis for judging future trends.
Copyright © 2026 Webull. All Rights Reserved